首页> 外文OA文献 >P573 Comparative effectiveness of second-line biological therapies for Ulcerative colitis and Crohn’s disease in patients with prior failure of anti-tumour necrosis factor treatment

【2h】

P573 Comparative effectiveness of second-line biological therapies for Ulcerative colitis and Crohn’s disease in patients with prior failure of anti-tumour necrosis factor treatment

机译：抗肿瘤坏死因子治疗患者溃疡性结肠炎二线生物疗法对溃疡性结肠炎和克罗恩病的比较有效性

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

著录项
引文网络
相似文献
相关主题

著录项

作者
H K Hyun; J Yu; E A Kang; J Park; S J Park; J J Park; T I Kim; W H Kim; J H Cheon;
展开▼
作者单位

展开▼
年度 2021
总页数
原文格式 PDF
正文语种
中图分类

相似文献

外文文献
中文文献
专利

1. Real-world clinical effectiveness and safety of vedolizumab and anti-tumor necrosis factor alpha treatment in ulcerative colitis and Crohn’s disease patients: a German retrospective chart review [J] . Ulf Helwig, Michael Mross, Stefan Schubert, BMC Gastroenterology . 2020,第1期

机译：Vedolizumab和抗肿瘤坏死因子α治疗溃疡性结肠炎和克罗恩病患者的现实世界临床疗效和安全性：德国回顾性图表
2. Effectiveness of adalimumab for the treatment of ulcerative colitis in clinical practice: comparison between anti-tumour necrosis factor-naive and non-naive patients [J] . Iborra Marisa, Perez-Gisbert Javier, Maia Bosca-Watts Marta, Journal of gastroenterology . 2017,第7期

机译：Adalimumab在临床实践中治疗溃疡性结肠炎的有效性：抗肿瘤坏死因子 - 幼稚和非天真患者的比较
3. Effectiveness of adalimumab for the treatment of ulcerative colitis in clinical practice: comparison between anti-tumour necrosis factor-naive and non-naive patients (vol 52, pg 788, 2017) [J] . Iborra Marisa, Gisbert Javier P., Bosca-Watts Marta Maia, Journal of gastroenterology . 2017,第7期

机译：Adalimumab在临床实践中治疗溃疡性结肠炎的有效性：抗肿瘤坏死因子 - 幼稚和非天真患者的比较（Vol 52，PG 788,2017）
4. Standard therapy for ulcerative colitis and Crohn's disease: the ECCO guidelines [C] . S. TRAVISA. IGNJATOVIC Falk Symposium . 2008

机译：溃疡性结肠炎和克罗恩病的标准疗法：ECCO指南
5. Biolo?ki Procesi in Napovedovanje Neodzivnosti Na Zaviralce Dejavnika Tumorske Nekroze Pri Crohnovi Bolezni z Integracijo Genomskih Podatkov =Biological processes and predicting non-response to tumor necrosis factor inhibitors in Crohn's disease by integr [D] . Jezernik, Gregor. 2021

机译：通过整合基因组数据=生物学过程和预测携带基因组疾病肿瘤疾病肿瘤坏死因子抑制剂的生物过程和预测性
6. Real-world clinical effectiveness and safety of vedolizumab and anti-tumor necrosis factor alpha treatment in ulcerative colitis and Crohn’s disease patients: a German retrospective chart review [O] . Ulf Helwig, Michael Mross, Stefan Schubert, 2020

机译：Vedolizumab和抗肿瘤坏死因子α治疗溃疡性结肠炎和克罗恩病患者的现实世界临床疗效和安全性：德国回顾性图表
7. DOP050. The efficacy of vedolizumab by disease activity and prior tumour necrosis factor-alpha antagonist failure in patients with ulcerative colitis or Crohn’s disease: post-hoc analyses from the GEMINI 1 and GEMINI 2 studies [O] . 2016

机译：DOP050。 Vedolizuab对疾病活动和肿瘤坏死因子-α患者溃疡性结肠炎或CROHN病患者的疗效和先前的肿瘤坏死因子 - 来自Gemini 1和Gemini 2研究的hoc分析

P573 Comparative effectiveness of second-line biological therapies for Ulcerative colitis and Crohn’s disease in patients with prior failure of anti-tumour necrosis factor treatment

著录项

引文网络

相似文献

相关主题

期刊订阅